Predictors for Severe Persisting Pain in Rheumatoid Arthritis Are Associated with Pain Origin and Appraisal of Pain
Overview
Authors
Affiliations
Objectives: To determine the proportion of patients with rheumatoid arthritis (RA) with severe persisting pain and to identify predictive factors despite treatment-controlled disease activity.
Methods: This prospective multicentre study included outpatients with RA scheduled for escalation of anti-inflammatory treatment due to active disease and severe pain (Disease Activity Score 28 (DAS28)>3.2 and Visual Analogue Scale (VAS)>50). At week 24, patients were stratified into reference group (DAS28 improvement>1.2 or DAS28≤3.2 and VAS pain score<50), non-responders (DAS28 improvement≤1.2 and DAS28>3.2, regardless of VAS pain score) and persisting pain group (DAS28 improvement>1.2 or DAS28≤3.2 and VAS pain score≥50). The former two subgroups ended the study at week 24. The latter continued until week 48. Demographic data, DAS28-C reactive protein, VAS for pain, painDETECT Questionnaire (PD-Q) to identify neuropathic pain (NeP) and the Pain Catastrophising Scale were assessed and tested for relation to persisting pain.
Results: Of 567 patients, 337 (59.4%) were classified as reference group, 102 (18.0%) as non-responders and 128 (22.6%) as patients with persisting pain. 21 (8.8%) responders, 28 (35.0%) non-responders and 27 (26.5%) persisting pain patients tested positive for NeP at week 24. Pain catastrophising (p=0.002) and number of tender joints (p=0.004) were positively associated with persisting pain at week 24. Baseline PD-Q was not related to subsequent persisting pain.
Conclusions: Persisting and non-nociceptive pain occur frequently in RA. Besides the potential involvement of NeP, pain catastrophising and a higher number of tender joints coincide with persisting pain.
Taylor P, Fakhouri W, Ogwu S, Haladyj E, de la Torre I, Fautrel B Rheumatol Ther. 2024; 12(1):109-122.
PMID: 39688792 PMC: 11751266. DOI: 10.1007/s40744-024-00732-8.
Direct Effects of the Janus Kinase Inhibitor Baricitinib on Sensory Neurons.
Vazquez E, Richter F, Natura G, Konig C, Eitner A, Schaible H Int J Mol Sci. 2024; 25(22).
PMID: 39596013 PMC: 11593535. DOI: 10.3390/ijms252211943.
Scott I, Babatunde O, Barker C, Beesley R, Beesley R, Birkinshaw H Rheumatol Adv Pract. 2024; 8(4):rkae128.
PMID: 39563967 PMC: 11573413. DOI: 10.1093/rap/rkae128.